OnKure Therapeutics (OKUR) AI Stock Analysis

• Market Cap: $43.22M
• Dividend Yield: N/A
• Average Volume (3M): 86.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: N/A
• EPS Growth: 46.20%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.09
• Shares Outstanding: 12,861,672
• 10 Day Avg. Volume: 131,167
• 30 Day Avg. Volume: 86,556
• PEG Ratio: -0.04
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.24
• Enterprise Value/Market Cap: 7.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -721.85
• Enterprise Value/Ebitda: -3.90
• 1Y Price Target: $25.50
• Price Target Upside: 699.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $3.00 ▼(-5.96% Downside)

The score is driven primarily by weak financial performance (no revenue, widening losses, and heavy cash burn implying continued funding risk), partially offset by low leverage and improved equity on the balance sheet. Technicals also detract due to a downtrend below major moving averages and negative MACD, while valuation support is limited because losses produce a negative P/E and no dividend yield is available.

Positive Factors

Very low leverage

Extremely low reported debt and near-zero debt-to-equity materially reduce interest burden and financial distress risk. This structural strength preserves strategic optionality for R&D funding and partnerships, improving resilience while the company advances clinical programs.

Capital flexibility via shelf

A $200M mixed securities shelf and ATM sales agreement provide durable access to capital markets, allowing the company to raise funds opportunistically to support trials. This structural financing tool reduces the immediacy of a single dilutive financing and supports execution of multi-arm clinical plans.

Advancing lead clinical program

Expanded trial arms and combination testing signal a deliberate clinical strategy to demonstrate differentiation for selective PI3Kα inhibition in earlier lines. Meaningful pipeline progression and planned data readouts create long-term value drivers independent of short-term market moves.

Negative Factors

Pre-revenue with widening losses

The company remains pre-revenue and incurred substantially larger net losses year-over-year, a structural challenge that increases reliance on external financing until commercialization or partnership milestones are achieved, constraining free-cash-flow generation for the foreseeable horizon.

High and increasing cash burn

Sustained and growing negative operating and free cash flow implies persistent funding need to sustain R&D and trials. Structurally high cash burn elevates dilution and financing risk, pressuring management to secure capital repeatedly before product revenues emerge.

Balance-sheet consumption

A material drop in total assets over the period indicates depletion of cash and resources to fund operations. Even with improved equity, declining assets shrink the margin of safety, limiting runway and increasing dependency on external capital or partnerships to sustain clinical development.

OnKure Therapeutics Business Overview & Revenue Model

Company Description

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

How the Company Makes Money

OnKure Therapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These agreements often include upfront payments, milestone payments based on the achievement of specific development or regulatory objectives, and royalties on future sales of successfully commercialized drugs. Additionally, OnKure may receive funding from government grants or research institutions to support its R&D activities. The company's revenue model is highly dependent on the progress and success of its clinical trials and the ability to secure strategic partnerships.

OnKure Therapeutics Financial Statement Overview

Summary

OnKure Therapeutics faces considerable financial management challenges, with persistent losses and no revenue. While recent improvements in equity and financing activity are positive signals, the company needs to focus on revenue generation and operational efficiency to achieve sustainable growth.

Income Statement

OnKure Therapeutics has not generated any revenue over the past three years, resulting in negative EBIT and net income figures. The lack of revenue and high operational losses indicate significant financial challenges and a need for strategic shifts to achieve profitability.

Balance Sheet

The company shows improvement in its equity position with positive stockholders' equity in the latest year, reversing the negative equity from previous years. However, the low debt levels relative to equity indicate limited leverage risk, albeit with significant liabilities. The equity ratio shows a strong position in total assets.

Cash Flow

The company exhibits strong cash flow management, with significant financing inflows enhancing cash reserves. Despite negative operating cash flow, the increase in cash and equivalents signals effective capital sourcing. However, substantial free cash outflows continue to reflect operational challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-419.00K	0.00	0.00	0.00	-50.00K	-37.00K
EBITDA	-77.62M	-51.71M	-34.75M	-29.38M	-39.72M	-19.43M
Net Income	-81.21M	-52.67M	-35.31M	-29.51M	-39.77M	-19.46M
Balance Sheet
Total Assets	72.83M	114.91M	35.73M	16.00M	154.02M	55.22M
Cash, Cash Equivalents and Short-Term Investments	70.33M	110.76M	29.88M	11.54M	147.67M	53.61M
Total Debt	687.00K	1.08M	674.00K	637.00K	0.00	92.72M
Total Liabilities	6.41M	11.08M	137.58M	70.42M	6.81M	97.34M
Stockholders Equity	66.43M	103.83M	-101.84M	-54.42M	147.21M	-42.12M
Cash Flow
Free Cash Flow	-61.42M	-51.17M	-34.79M	-28.09M	-38.18M	-18.56M
Operating Cash Flow	-61.33M	-51.12M	-34.55M	-26.95M	-37.98M	-18.54M
Investing Cash Flow	-45.41M	15.87M	-246.00K	-1.13M	-23.38M	7.38M
Financing Cash Flow	114.14M	116.13M	53.13M	26.46M	132.41M	47.27M

OnKure Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKUR, the sentiment is Positive. The current price of 3.19 is above the 20-day moving average (MA) of 2.95, above the 50-day MA of 2.97, and above the 200-day MA of 2.71, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 50.82 is Neutral, neither overbought nor oversold. The STOCH value of 59.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OKUR.

OnKure Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ELUT	48 Neutral	$36.04M	-0.89	―	―	-14.92%	72.81%
IGC	47 Neutral	$28.72M	-3.73	-83.34%	―	-6.51%	58.31%
OKUR	42 Neutral	$43.22M	-0.49	-115.64%	―	―	46.20%
RANI	41 Neutral	$170.13M	-1.76	―	―	―	25.08%

OnKure Therapeutics Corporate Events

OnKure Therapeutics Announces Sales Agreement with Leerink

On November 6, 2025, OnKure Therapeutics, Inc. announced a sales agreement with Leerink Partners LLC to sell shares of its Class A common stock through an ‘at the market offering’ program. This agreement allows OnKure to set parameters for share sales, with Leerink Partners acting as the sales agent. The arrangement provides flexibility for OnKure to manage its capital needs and market presence, potentially impacting its financial operations and stakeholder interests.

The most recent analyst rating on (OKUR) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on OnKure Therapeutics stock, see the OKUR Stock Forecast page.